Zenflow is developing a minimally invasive procedure for treating benign prostatic hyperplasia (BPH) that eliminates the need for burning, cutting, or piercing tissue, resulting in minimal bleeding. Clinical studies indicate that patients experience significant symptom relief and recover within hours, offering a patient-friendly alternative to traditional BPH treatments.
Funding
$24M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CMFounders
Product
Problem
Benign prostatic hyperplasia (BPH), or enlarged prostate, affects over half of men over 50, often leading to bothersome symptoms. Current BPH treatments, including medications and minimally invasive therapies, can have unwanted side effects or be uncomfortable for patients.
Solution
Zenflow is developing a minimally invasive procedure for BPH designed to provide lasting symptom relief and fast procedural recovery. The Zenflow procedure avoids burning, cutting, or piercing tissue, resulting in minimal bleeding and reduced discomfort. Clinical studies have demonstrated that patients experience significant symptom relief and typically recover within hours, offering a patient-friendly alternative to traditional BPH treatments. This approach aims to improve the patient experience and outcomes compared to existing BPH treatment options.
Target Audience
The primary target audience includes men over 50 experiencing symptoms of benign prostatic hyperplasia (BPH) and urologists seeking safer, more effective treatment options for their patients.
Features
- Minimally invasive procedure for treating BPH
- Gentle approach that avoids burning, cutting, or piercing tissue
- Minimal bleeding during the procedure
- Long-term benefits and lasting symptom relief
- Fast recovery time, with most patients recovering within hours